SECURITIES AND EXCHANGE COMMISSION
FORM 8-K
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
March 23, 2004
CONNETICS CORPORATION
| Delaware | 0-27406 | 94-3173928 | ||
| (State or Other | (Commission File | (IRS Employer Identification | ||
| Jurisdiction of | No.) | No.) | ||
| Incorporation) |
3290 West Bayshore Road, Palo Alto, California 94303
(Address of principal executive offices, including zip code)
(650) 843-2800
(Registrant’s telephone number, including area code)
1
| Item 5. Other Events. | ||||||||
| Item 7. Financial Statements and Exhibits. | ||||||||
| SIGNATURES | ||||||||
| EXHIBIT INDEX | ||||||||
| EXHIBIT 99.1 | ||||||||
Item 5. Other Events.
On March 23, 2004, Connetics Corporation announced the positive outcome of its Phase III clinical trials evaluating Velac® in the topical treatment of acne vulgaris. Velac is a first-in-class, once-a-day treatment combination of 1% clindamycin and 0.025% tretinoin in an aqueous gel.
A copy of the press release announcing this event is attached to this Report as Exhibit 99.1 and is incorporated into this report by this reference.
Item 7. Financial Statements and Exhibits.
(c) Exhibits.
| 99.1 | Press Release dated March 23, 2004. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| CONNETICS CORPORATION |
||||
| By: | /s/ Katrina J. Church | |||
| Katrina J. Church
Executive Vice President, General Counsel and Secretary |
||||
Date: March 24, 2004